CatalystPit
TerminalPit ConsensusInsidersPoliticiansInstitutionsNewsScreener

SGMTSagimet Biosciences Inc.

NASDAQ · Pharmaceutical Preparations
Last close $9.88 · 2026-09-30
ABOUT
ExchangeNASDAQ
SectorHealthcare
IndustryPharmaceutical Preparations
RECENT INSIDER TRADES
  • 2026-08-17 · Kemble George (Director) · SELL
  • 2026-08-17 · Kemble George (Director) · OTHER
  • 2026-08-12 · Kemble George (Director) · OTHER
INSTITUTIONAL OWNERSHIP
Institutional holders128
Shares held53,220,361
Value$403.90M
Percent of shares outstanding173.50%
As of quarter end2026-06-30
RECENT NEWS
  • Sagimet to present denifanstat Phase 3 results at 2026 dermatology conference
  • SGMT: Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
  • Citizens cuts Sagimet Biosciences stock price target
  • Sagimet Biosciences presents 52-week Phase 3 data for denifanstat in acne
  • Why is Sagimet Biosciences stock rallying today?
CatalystPit
FeaturesComing soonPricingComing soonPrivacyTermsDisclaimerAffiliate TermsContact
2026 CATALYSTPIT · NOT FINANCIAL ADVICE · DELAYED FILINGS
Sagimet Biosciences Inc. (SGMT) · Stock Price, Insider Trades, Institutional Holdings · CatalystPit